The promise of a new and better class of mental health therapies lies within the chemistry of psychedelic compounds. Our mission is to unlock it. We're developing safe, FDA, EMA and Health Canada approved therapies for neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines that have the potential to deliver greater impact than current first-line treatments. Our first clinical program is focused on accessible psilocybin-based drugs that deliver rapid therapeutic outcomes without perceptual side effects. By eliminating the side effects, this intervention can be administered to a broad cohort of patients.